Re: Lange T et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Leukemia 2004; 89: 49-57

Haematologica. 2004 Aug;89(8):ELT12.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Cytogenetics / methods*
  • DNA, Complementary / genetics
  • Drug Monitoring / methods
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • RNA, Neoplasm / genetics
  • Reverse Transcriptase Polymerase Chain Reaction / methods*

Substances

  • Antineoplastic Agents
  • Benzamides
  • DNA, Complementary
  • Piperazines
  • Pyrimidines
  • RNA, Neoplasm
  • Imatinib Mesylate